Author

Meixiao Long

The Ohio State UniversityORCID 0000-0002-0820-5612Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Bingwei WangiD· 1 shared Ho Man ChaniD· 1 shared Janos Laszlo TanyiiD· 1 shared Jianfeng SheniD· 1 shared Jiao YuaniD· 1 shared Jie Sheng HuangiD· 1 shared Junjie JiangiD· 1 shared Kathleen T. MontoneiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bingwei WangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyeLifePeer-reviewedJul 17, 2024

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

Youyou Zhang, Mu Xu, Jiao Yuan…·Xiaowen Hu

This study identifies PRMT inhibitors as effective combinational therapies with PARP inhibitors to sensitize HR-proficient ovarian and breast cancer cells to treatment.

8 citations

humanbulk RNA-seq

𝕏 PostBluesky